Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
EXACT Therapeutics AS ( (DE:56F) ) has issued an update.
EXACT Therapeutics has received a unanimous positive safety conclusion from the Trial Monitoring Committee for the first safety cohort in its Phase 2 ENACT trial in first-line locally advanced pancreatic cancer, allowing the study of PS101 in combination with modified FOLFIRINOX to proceed as planned. Early trial data show encouraging tumour shrinkage and an unaudited reduction of more than 85% in the tumour biomarker CA 19-9, prompting the committee to recommend testing a higher PS101 dose of 60 µl/kg in a new safety cohort before full enrolment, while most sites are now open and an interim efficacy read-out is expected mid-2026; the safety milestone also triggers the potential exercise of up to 50.6 million warrants from a prior private placement, which could provide additional funding and influence the company’s capital structure as it advances its pancreatic cancer programme in the US and UK.
More about EXACT Therapeutics AS
EXACT Therapeutics AS is a clinical-stage precision medicine company listed on Euronext Growth Oslo that uses ultrasound to activate its proprietary drug candidate PS101, aiming to enhance the effect of oncology treatments and potentially other indications such as brain diseases. The company’s platform is designed to be combined with a broad range of therapeutic agents, positioning it within the emerging field of ultrasound-mediated drug delivery in cancer care.
Average Trading Volume: 41,697
Current Market Cap: NOK118.3M
Learn more about 56F stock on TipRanks’ Stock Analysis page.